Report of the UK Cystic Fibrosis Trust Antibiotic Working Group

8. PHARMACOPOEIAOriginally based on a document prepared by Amanda Bevan (Southampton). We are also grateful toPaula Hayes (Liverpool) and Helen Cunliffe (Leeds) for their advice. Also we thank ChurchillLivingstone, publishers of Practical Guidelines for Cystic Fibrosis Care. 1If clinicians are unfamiliar with using a particular drug, it is important they read the summary ofproduct characteristics (SPC) and discuss the drug’s use with the pharmacist involved with theirSpecialist CF Centre or CF Clinic and the hospital microbiology department. The SPC may be foundin the electronic medicines compendium (http://emc.medicines.org.uk). Helpful guidance can also befound in the British National Formulary (http://www.bnf.org) and the British National Formulary forChildren (http://bnfc.org)8.1 Continuous anti-staphylococcal therapyFlucloxacillin orallyAge Dose FrequencyBirth to 3 year 125 mg 12 hourlyRecurrent growth of MSSA 50 mg/kg 12 hourlyPreparationsAdministrationSide-effectsNotes250 mg and 500 mg capsules, 125 mg/5 ml and 250 mg/5 ml suspensions(some children find Floxapen brand more palatable).Take an hour before food or on an empty stomach.Gastrointestinal upset and rarely sensitivity reactions. Hepatitis and cholestatic jaundice have been reportedand may occur up to 2 months after stopping treatment.Reduce dose or frequency in renal impairment – see specialist texts.8.2 Treatment of asymptomatic Staphylococcus aureus isolates or minorexacerbationsFlucloxacillin orallyAge Dose FrequencyUnder 18 years 25 mg/kg (total daily dose may be given in 3 divided doses) 6 hourlyAdult 1–2 g 6 hourlyAdditional Information: section 4.2.4Cystic Fibrosis Trust 8.0March 2009